
BBU Stock Forecast & Price Target
BBU Analyst Ratings
Bulls say
Brookfield Business Partners LP exhibits strong financial growth and performance characterized by effective financial de-leveraging within its investment portfolio, indicating potential valuation upside. The company has a substantial investment portfolio, which, alongside improvements in organic growth and margin expansion, enhances investor confidence and could positively impact its share price. Additionally, the significant capital deployment and historical investment performance suggest attractive net asset value (NAV) growth, contributing to a favorable outlook for the stock.
Bears say
Brookfield Business Partners LP is experiencing a negative outlook primarily due to revised EBITDA forecasts, which highlight ongoing challenges in key segments such as Healthscope, DexKo, and CDK Global, where management anticipates adverse market conditions and rising operational costs. The company's EBITDA for the Industrial segment surpassed expectations in Q4/24 at $306 million; however, this figure is juxtaposed against a significant reduction in overall EBITDA projections for both years. Furthermore, in the Infrastructure Services segment, Q4/24 EBITDA of $160 million fell short of the previous year's performance of $184 million and only modestly exceeded the forecast, indicating potential vulnerabilities within its operational structure.
This aggregate rating is based on analysts' research of Brookfield Business Partners and is not a guaranteed prediction by Public.com or investment advice.
BBU Analyst Forecast & Price Prediction
Start investing in BBU
Order type
Buy in
Order amount
Est. shares
0 shares